drug · antibody
sonesitatug vedotin
Phase 3updated 6mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Unknown, with 1 investigational indication.
all catalysts(0)
nothing on the calendar yet
Trials studying sonesitatug vedotin
- phase3Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- phase2A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
News(10)
- Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdictWith companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major bac…biospace · 15d ago
- ESMO: AstraZeneca exec insists phase 3 ADC data ‘robust’ enough for regulators despite PFS missAn AstraZeneca executive was adamant that detailed data from a phase 3 study of the pharma’s next-generation antibody-drug conjugate are “robust” enough to take to regulators, despite the trial fai…fiercebiotech · 24d ago
- Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xV…biospace · 29d ago
- Summit snags $2B investment from AstraZeneca, clearing financial overhangThe all-stock deal gives Summit Therapeutics enough money to see through Phase 3 trials for the PD-1/VEGF bispecific ivonescimab—but keeps the asset fully in-house without giving up licensing rights.biospace · 1mo ago
- AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combosAstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with antibody-drug conjugates (ADCs). The newly minted pa…fiercebiotech · 1mo ago
- AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowAstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.biospace · 3mo ago
- AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowAstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.biospace · 3mo ago
- FDA scientists question Capricor data; Legend CEO steps downCapricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…biopharma_dive · 3mo ago
- AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failureAstraZeneca remains "very much on track" to hit its 2030 goal of reaching $80 billion in revenue despite the recent late-stage failure of Wainua in ATTR-cardiomyopathy, CEO Pascal Soriot said durin…biospace · 3mo ago
- AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidatesAstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.fiercebiotech · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that